Relugolix

also known as TAK-385 · Orgovyx · [14C]-TAK-385 · Relugolix component of myfembree

Small molecule targets GNRHR via inhibition

Developed for: prostate cancer · endometriosis · leiomyoma · prostate adenocarcinoma · prostate carcinoma · metastatic prostate carcinoma · pelvis syndrome · benign neoplasm of corpus uteri
+4 more
· castration-resistant prostate carcinoma · menstrual disorder · uterine benign neoplasm · uterine corpus leiomyoma
Investigated by: Myovant Sciences GmbH · Takeda · Pfizer · National Cancer Institute (NCI) · Sumitomo Pharma America, Inc. · Millennium Pharmaceuticals, Inc.
+36 more
· Sumitomo Pharma Switzerland GmbH · Bayer · Emory University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · NYU Langone Health · National Comprehensive Cancer Network · Prostate Cancer Foundation · University of Chicago · ASKA Pharmaceutical Co., Ltd. · AdventHealth · Astellas Pharma Inc · Atish Choudhury, MD · Baptist Health South Florida · Blue Earth Diagnostics · Dana-Farber Cancer Institute · Debiopharm International SA · Endeavor Health · Insel Gruppe AG, University Hospital Bern · Janssen Research & Development, LLC · Mayo Clinic · NRG Oncology · National Cancer Institute, Naples · National Institutes of Health (NIH) · Ohio State University Comprehensive Cancer Center · Oregon Health and Science University · Qilu Pharmaceutical Co., Ltd. · Sean Sachdev · University Hospital, Geneva · University of Bern · University of Kansas Medical Center · University of Miami · University of Michigan · University of Oklahoma · University of Utah · Varian Medical Systems · Werner und Hedy Berger-Janser - Stiftung

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	ORGOVYX	—	2024-10-18	fda.gov ↗
Approved	EU (EMA)	Ryeqo	—	2021-07-16	europa.eu ↗
Approved	US (FDA)	ORGOVYX	—	2020-12-18	fda.gov ↗

Trials 53

today

US approved 2020

EU approved 2021

NCT07801664 · Ph 2 NCT07455903 · Ph 2 NCT07111247 · Ph 4 NCT07100782 · Ph 3 NCT07302451 · Ph 2 NCT07216248 · Ph 2 NCT07173127 · not/applicable NCT07025369 · Ph 2 NCT06650579 · Ph 3 NCT06130995 · Ph 1 NCT06463457 · Ph 2 NCT06111313 · Ph 2 NCT06631521 · Ph 1 NCT06499870 · Ph 2 NCT06330805 · Ph 2 NCT06279195 · Ph 2 NCT06397703 · Ph 2 NCT05765500 · Ph 2 NCT06671548 · Ph 3 NCT06129851 · Ph 2 NCT05862272 · Ph 3 NCT05746806 · not/applicable NCT05679388 · Ph 1 NCT05605964 · Ph 3 NCT05538689 · Ph 4 NCT05320406 · Ph 2 NCT05053152 · Ph 2 NCT04756037 · Ph 3 NCT04666129 · Ph 1 NCT04714554 · Ph 1 NCT04523207 · Ph 2 NCT03931915 · Ph 3 NCT03751124 · Ph 3 NCT03654274 · Ph 3 NCT03204318 · Ph 3 NCT03204331 · Ph 3 NCT03412890 · Ph 3 NCT03103087 · Ph 3 NCT03049735 · Ph 3 NCT03085095 · Ph 3 NCT02792062 · Ph 1 NCT04978688 · Ph 1 NCT02655224 · Ph 3 NCT02655237 · Ph 3 NCT02396147 · Ph 1 NCT02252354 · Ph 1 NCT02135445 · Ph 2 NCT02141659 · Ph 1 NCT02083185 · Ph 2 NCT02093390 · Ph 1 NCT01452685 · Ph 2 NCT01452659 · Ph 2 NCT01458301 · Ph 2

20122013201420152016201720182019202020212022202320242025202620272028202920302031

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 111 trials
Phase 1	NCT06130995	Dec 2024 → Jan 2029 expected	—	University of Oklahoma	Recruiting	No outcome recorded
Phase 1	NCT06631521	Oct 2024 → Jun 2026 overdue	prostate adenocarcinoma	AdventHealth	Recruiting	No outcome recorded
Phase 1	NCT05679388	Feb 2023 → Aug 2024	prostate adenocarcinoma	University of Chicago	Terminated	No outcome recorded
Phase 1	NCT04666129	Feb 2021 → May 2024	castration-resistant prostate carcinoma, metastatic prostate carcinoma	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 1	NCT04714554	Jan → Mar 2021	—	Myovant Sciences GmbH	Completed	No outcome recorded
Phase 1	NCT02792062	Jul → Aug 2016	—	Takeda	Completed	No outcome recorded
Phase 1	NCT04978688	Jun → Sep 2016	—	Myovant Sciences GmbH	Completed	No outcome recorded
Phase 1	NCT02396147	Mar → Apr 2015	—	Takeda	Completed	No outcome recorded
Phase 1	NCT02252354	Sep → Oct 2014	—	Takeda	Completed	No outcome recorded
Phase 1	NCT02141659	May 2014 → Apr 2017	prostate carcinoma	Takeda	Completed	No outcome recorded
Phase 1	NCT02093390	Mar → Apr 2014	endometriosis, prostate cancer	Millennium Pharmaceuticals, Inc.	Completed	No outcome recorded

Phase 221 trials · 2 met primary
Phase 2	NCT07801664	Aug 2026 → Aug 2028 expected	prostate cancer	NYU Langone Health	Recruiting	No outcome recorded
Phase 2	NCT07455903	Apr 2026 → Oct 2029 expected	prostate carcinoma	Baptist Health South Florida	Recruiting	No outcome recorded
Phase 2	NCT07302451	Dec 2025 → May 2027 expected	prostate adenocarcinoma	National Cancer Institute, Naples	Active not recruiting	No outcome recorded
Phase 2	NCT07216248	Oct 2025 → Oct 2030 expected	metastatic prostate carcinoma	University of Utah	Recruiting	No outcome recorded
Phase 2	NCT07025369	Aug 2025 → Jan 2029 expected	prostate adenocarcinoma	Mayo Clinic	Recruiting	No outcome recorded
Phase 2	NCT06463457	Dec 2024 → Nov 2028 expected	prostate cancer	Atish Choudhury, MD	Active not recruiting	No outcome recorded
Phase 2	NCT06111313	Nov 2024 → Nov 2028 expected	prostate cancer	University of Miami	Recruiting	No outcome recorded
Phase 2	NCT06499870	Sep 2024 → Nov 2030 expected	prostate adenocarcinoma	Sean Sachdev	Recruiting	No outcome recorded
Phase 2	NCT06330805	Aug 2024 → Dec 2027 expected	prostate adenocarcinoma	Ohio State University Comprehensive Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT06279195	Jun 2024 → Nov 2025	pelvis syndrome	Endeavor Health	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT06397703	Apr 2024 → Apr 2030 expected	prostate cancer	NYU Langone Health	Recruiting	No outcome recorded
Phase 2	NCT05765500	Feb 2024 → Jul 2027 expected	prostate cancer	Dana-Farber Cancer Institute	Recruiting	No outcome recorded
Phase 2	NCT06129851	Nov 2023 → Oct 2025 overdue	prostate cancer	University of Kansas Medical Center	Not yet recruiting	No outcome recorded
Phase 2	NCT05320406	Jun 2022 → Jan 2025 overdue	prostate carcinoma	Emory University	Active not recruiting	Met primary
Phase 2	NCT05053152	Apr 2022 → Feb 2029 expected	metastatic prostate carcinoma, prostate adenocarcinoma	NRG Oncology	Active not recruiting	No outcome recorded
Phase 2	NCT04523207	Aug 2020 → Oct 2023	prostate cancer	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT02135445	Jun 2014 → Dec 2015	prostate cancer	Millennium Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02083185	Mar 2014 → Jan 2016	prostate cancer	Millennium Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01452685	Mar 2012 → Dec 2013	endometriosis	Takeda	Completed	No outcome recorded
Phase 2	NCT01452659	Oct 2011 → Sep 2012	leiomyoma	Takeda	Completed	Met primary
Phase 2	NCT01458301	Oct 2011 → Aug 2013	endometriosis	Takeda	Completed	No outcome recorded

Phase 317 trials · 9 met primary
Phase 3	NCT07100782	Dec 2025 → Aug 2028 expected	endometriosis, pelvis syndrome	University of Michigan	Recruiting	No outcome recorded
Phase 3	NCT06650579	Jan 2025 → Jul 2029 expected	prostate carcinoma	Emory University	Recruiting	No outcome recorded
Phase 3	NCT06671548	Jan 2024 → Nov 2026 expected	leiomyoma	Qilu Pharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT05862272	Aug 2023 → Jul 2029 expected	endometriosis, leiomyoma	Sumitomo Pharma Switzerland GmbH	Recruiting	No outcome recorded
Phase 3	NCT05605964	Jan 2023 → Dec 2024	prostate cancer	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT04756037	Mar 2021 → Feb 2025	—	Sumitomo Pharma Switzerland GmbH	Completed	No outcome recorded
Phase 3	NCT03931915	May 2019 → Jun 2020	endometriosis	ASKA Pharmaceutical Co., Ltd.	Completed	Met primary
Phase 3	NCT03751124	Oct 2018 → Feb 2021	uterine corpus leiomyoma	Myovant Sciences GmbH	Completed	Met primary
Phase 3	NCT03654274	May 2018 → Dec 2021	endometriosis	Myovant Sciences GmbH	Completed	No outcome recorded
Phase 3	NCT03204318	Dec 2017 → Jun 2020	endometriosis	Myovant Sciences GmbH	Completed	Met primary
Phase 3	NCT03204331	Nov 2017 → Apr 2020	endometriosis	Myovant Sciences GmbH	Completed	Met primary
Phase 3	NCT03412890	Oct 2017 → Jan 2020	leiomyoma	Myovant Sciences GmbH	Completed	No outcome recorded
Phase 3	NCT03103087	Jun 2017 → Jul 2019	leiomyoma	Myovant Sciences GmbH	Completed	Met primary
Phase 3	NCT03049735	Apr 2017 → Apr 2019	leiomyoma	Myovant Sciences GmbH	Completed	Met primary
Phase 3	NCT03085095	Apr 2017 → Oct 2019	prostate cancer	Myovant Sciences GmbH	Completed	Met primary
Phase 3	NCT02655224	Mar 2016 → May 2017	leiomyoma	Takeda	Completed	Met primary
Phase 3	NCT02655237	Mar 2016 → May 2017	benign neoplasm of corpus uteri	Takeda	Completed	Met primary

Phase 42 trials
Phase 4	NCT07111247	Jan 2026 → Aug 2027 expected	—	Oregon Health and Science University	Recruiting	No outcome recorded
Phase 4	NCT05538689	Nov 2022 → Oct 2024	leiomyoma, menstrual disorder	University of Chicago	Withdrawn	No outcome recorded
Phase not applicable2 trials
—	NCT07173127	Sep 2025 → Dec 2026 expected	uterine benign neoplasm	University Hospital, Geneva	Recruiting	No outcome recorded
—	NCT05746806	Mar 2023 → Nov 2027 expected	prostate carcinoma	Insel Gruppe AG, University Hospital Bern	Active not recruiting	No outcome recorded
Comparator or background therapy19 trials
Phase 0	NCT07069465 Comparator	Jun → Nov 2024	prostate cancer	Urology Clinics of North Texas	Completed	No outcome recorded
Phase 1	NCT06531499 Background	Nov 2024 → Nov 2028 expected	prostate carcinoma	Novartis Pharmaceuticals	Recruiting	No outcome recorded
Phase 1	NCT06379217 Background	Jul 2024 → Sep 2026 overdue	prostate neuroendocrine neoplasm	Novartis Pharmaceuticals	Active not recruiting	No outcome recorded
Phase 1/2	NCT06312761 Background	Jun 2024 → Dec 2025	hypogonadism, male	University of Washington	Unknown	No outcome recorded
Phase 2	NCT07142551 Background	Mar 2026 → Jun 2030 expected	castration-resistant prostate carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Recruiting	No outcome recorded
Phase 2	NCT06922318 Background	Aug 2025 → Aug 2031 expected	castration-resistant prostate carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Recruiting	No outcome recorded
Phase 2	NCT06528210 Background	Apr 2025 → Jun 2026	prostate adenocarcinoma	OHSU Knight Cancer Institute	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT06734130 Background	Jan 2025 → Jan 2029 expected	metastatic prostate carcinoma	H. Lee Moffitt Cancer Center and Research Institute	Active not recruiting	No outcome recorded
Phase 2	NCT06378866 Comparator	Jun 2024 → Feb 2031 expected	castration-resistant prostate carcinoma	Mayo Clinic	Recruiting	No outcome recorded
Phase 2	NCT06111781 Comparator	Apr 2024 → Feb 2028 expected	prostate cancer	Yale University	Recruiting	No outcome recorded
Phase 2	NCT06059118 Background	Oct 2023 → Jan 2027 expected	prostate cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Recruiting	No outcome recorded
Phase 2	NCT05189457 Background	Jan 2022 → Jul 2027 expected	prostate cancer	H. Lee Moffitt Cancer Center and Research Institute	Active not recruiting	No outcome recorded
Phase 2/3	NCT04787744 Background	Jul 2021 → Sep 2026 overdue	metastatic prostate carcinoma	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 3	NCT06439524 Comparator	Aug 2024 → Jun 2028 expected	endometriosis	Main Line Health	Recruiting	No outcome recorded
Phase 3	NCT05050084 Background	Dec 2021 → Nov 2026 expected	prostate adenocarcinoma	NRG Oncology	Active not recruiting	No outcome recorded
Phase 3	NCT04513717 Background	Jan 2021 → Dec 2033 expected	prostate adenocarcinoma	NRG Oncology	Active not recruiting	No outcome recorded
Phase 3	NCT04423211 Background	Oct 2020 → Dec 2032 expected	metastatic prostate carcinoma, prostate adenocarcinoma	ECOG-ACRIN Cancer Research Group	Recruiting	No outcome recorded
—	NCT07142967 Background	Aug 2025 → Aug 2028 expected	prostate cancer	NYU Langone Health	Recruiting	No outcome recorded
—	NCT05628363 Background	Jan 2023 → Oct 2025 overdue	prostate cancer	Washington University School of Medicine	Active not recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 13

Date	Issuer	Release
2026-06-22	ASKA Pharmaceutical Co., Ltd.	Results relugolix 配合剤（AKP-022）の子宮筋腫患者を対象とした国内第 3 相臨床試験結果のお知らせ aska-pharma.co.jp ↗
2022-08-05	Pfizer	Regulatory Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis pfizer.com ↗ MYFEMBREE (relugolix, estradiol, and norethindrone acetate) is a once-daily oral treatment approved by the U.S. Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
2022-06-17	Pfizer	Results Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain pfizer.com ↗ As previously reported, both studies achieved their co-primary endpoints by demonstrating clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain in women with endometriosis.
2022-06-02	Pfizer	Regulatory Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® pfizer.com ↗
2022-05-06	Pfizer	Regulatory Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis pfizer.com ↗
2022-04-12	Pfizer	Regulatory Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis pfizer.com ↗ The FDA noted that the letter does not reflect a final decision on the pending sNDA and that the application is still under review.
2021-09-09	Pfizer	Regulatory Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis pfizer.com ↗
2021-05-26	Pfizer	Regulatory Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids pfizer.com ↗ The FDA approval of MYFEMBREE represents a significant milestone in expanding treatment options for uterine fibroids, a chronic and debilitating disease for many women in the U.S.
2021-03-24	Pfizer	Results Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids pfizer.com ↗ 78.4% of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who discontinued treatment at Week 52 (p < 0.0001)
2021-02-17	Pfizer	Results Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids pfizer.com ↗ In the LIBERTY studies, relugolix combination therapy improved the most bothersome symptoms of uterine fibroids and had a well-tolerated safety profile including maintenance of bone mineral density comparable to placebo.
2021-01-26	Pfizer	Results Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis pfizer.com ↗ 84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year
2017-11-09	Takeda	Results Takeda Announces Positive Results from its Phase 3 Clinical Trial in Japan Evaluating the Efficacy and Safety of Relugolix in the Treatment of Pain Symptoms Associated with Uterine Fibroids takeda.com ↗ Takeda Pharmaceutical Company Limited [ TSE: 4502 ] (“Takeda”) today announced that a Phase 3 clinical trial (“TAK-385-3008 Study”) evaluating the efficacy and safety of relugolix (generic name, development code: TAK-385), a gonadotropin-releasing hormone (GnRH) receptor antagonist, met the primary endpoint of statistical significance in improvement of pain symptoms associated with uterine fibroids compared to the control group.
2017-10-03	Takeda	Results Takeda Announces Positive Results from its Phase 3 Confirmatory Clinical Trial in Japan Evaluating the Efficacy and Safety of GnRH Receptor Antagonist Relugolix in Uterine Fibroids takeda.com ↗

All press releases naming this drug 18 releases

Date	Issuer	Release
2026-06-22	ASKA Pharmaceutical Co., Ltd.	relugolix 配合剤（AKP-022）の子宮筋腫患者を対象とした国内第 3 相臨床試験結果のお知らせ aska-pharma.co.jp ↗
2022-08-05	Pfizer	Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis pfizer.com ↗
2022-06-17	Pfizer	Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain pfizer.com ↗
2022-06-02	Pfizer	Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® pfizer.com ↗
2022-05-06	Pfizer	Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis pfizer.com ↗
2022-04-12	Pfizer	Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis pfizer.com ↗
2021-10-19	Pfizer	Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress pfizer.com ↗
2021-09-09	Pfizer	Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis pfizer.com ↗
2021-05-26	Pfizer	Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids pfizer.com ↗
2021-04-12	Pfizer	Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet pfizer.com ↗
2021-03-24	Pfizer	Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids pfizer.com ↗
2021-02-17	Pfizer	Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids pfizer.com ↗
2021-01-26	Pfizer	Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis pfizer.com ↗
2020-12-28	Sumitomo Pharma America, Inc.	Consolidated Subsidiary Myovant and Pfizer Enter Into Collaboration to Develop and Commercialize Relugolix sumitomo-pharma.com ↗
2020-12-28	Pfizer	Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health pfizer.com ↗
2018-05-31	Takeda	ASKA and Takeda Enter into Licensing Agreement for Relugolix in Women's Health Indications takeda.com ↗
2017-11-09	Takeda	Takeda Announces Positive Results from its Phase 3 Clinical Trial in Japan Evaluating the Efficacy and Safety of Relugolix in the Treatment of Pain Symptoms Associated with Uterine Fibroids takeda.com ↗
2017-10-03	Takeda	Takeda Announces Positive Results from its Phase 3 Confirmatory Clinical Trial in Japan Evaluating the Efficacy and Safety of GnRH Receptor Antagonist Relugolix in Uterine Fibroids takeda.com ↗

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 74 sources stand behind the page.

Field	Value	Cited text
Known as	relugolix	“Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout...” NCT06922318 ↗ 61 “Ryeqo® consists of an oral treatment, available as a pill, which contains 40 mg of the GnRH antagonist Relugolix, combined with 1 mg of oestradiol and a progestin, such as...” NCT07173127 ↗ “The aim of this study was to evaluate the efficacy and safety of three dose levels of oral relugolix, a small molecule GnRH receptor antagonist, in Japanese women with uterine...” PMID 34711224 ↗ Oct 2021 “luteinizing hormone-releasing hormone (LHRH) agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix)” NCT06059118 ↗ “ADT will be delivered with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.” NCT07801664 ↗ “Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.” NCT05538689 ↗ “ADT will be administered via Leuprolide or Degarelix monthly injections or daily Relugolix pills.” NCT07142967 ↗ “ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix).” NCT05628363 ↗ “GNRH agonist (leuprolide, goserelin, triptorelin) or GNRH antagonist (relugolix, degarelix)” NCT06528210 ↗ “abarelix, degarelix, or relugolix” NCT06379217 ↗ “Degarelix, Relugolix” NCT06531499 ↗ Show 51 more sources
Known as	[14C]-TAK-385	“[14C]-TAK-385 Oral Solution” NCT02252354 ↗
Known as	Orgovyx	“e.g. Orgovyx® Tablets 120mg; first day 360mg, after second day 120mg per day” NCT05746806 ↗ 2 “LHRH agonist or antagonist (e.g. Eligard, Zoladex, Lupron, Orgovyx)” NCT07142551 ↗ “Relugolix 120 MG [Orgovyx]” NCT06111781 ↗
Known as	Relugolix component of myfembree	ChEMBL registry synonym — accepted as the source's own label CHEMBL1800159 ↗
Known as	TAK-385	“The purpose of this study is to determine the efficacy and safety of TAK-385, once daily (QD), for 12 weeks in women with endometriosis.” NCT01458301 ↗ 10 “The drug being tested in this study is called relugolix (TAK-385).” NCT02083185 ↗ “TAK-385 40 mg tablets + Leuprorelin acetate placebo injection” NCT03931915 ↗ NCT01452659 ↗ NCT01452685 ↗ NCT02792062 ↗ NCT02135445 ↗ NCT02141659 ↗ NCT02396147 ↗ NCT02252354 ↗ NCT02093390 ↗
Action	Inhibit	“Gonadotropin-releasing hormone receptor antagonist” CHEMBL1800159 ↗ 1 “a small molecule GnRH receptor antagonist” PMID 34711224 ↗ Oct 2021
Modality	Small molecule	“a small molecule GnRH receptor antagonist” PMID 34711224 ↗ Oct 2021 1 CHEMBL1800159 ↗
Route	Oral	“Patients were randomized 1:1:1:1 to relugolix 10, 20, or 40 mg, or placebo, orally once daily for 12 weeks.” PMID 34711224 ↗ Oct 2021
Target	GNRHR	“Gonadotropin-releasing hormone receptor antagonist” CHEMBL1800159 ↗